Clinical experience with a novel anchored, frameless copper-releasing contraceptive device for intra-caesarean insertion.

What Was Tested

This clinical trial looks at Copper (Supplement).

The primary objective of the study was to determine the expulsion rate of the newly developed frameless GyneFix Caesarean Section (Gyn-CS®) device, specifically developed to minimise expulsion when inserted immediately after delivery of the placenta during caesarean section.

Secondary objectives included evaluation of side effects, patient's satisfaction with the method and continuation of use.

Who Took Part

PubMed indexes the participants as adults, women only.

How the Study Was Run

A prospective, non-randomised clinical trial was conducted at a single university hospital research centre in Istanbul, Turkey, with follow-up at 4-6 weeks and again at 3 months.

What Was Measured

The subject headings attached to it are Aftercare, Cesarean Section, Contraception, Contraceptive Effectiveness, Intrauterine Device Expulsion, Intrauterine Devices, Copper and Postpartum Period.

Author keywords: Anchoring technology, IUD expulsion, caesarean section, frameless IUD and postpartum IUD insertion.

What This Means in Plain Language

This is a clinical trial of Copper (Supplement).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.